KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Capital Expenditures for 4 consecutive years, with $3.4 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Capital Expenditures fell 86.56% year-over-year to $3.4 million, compared with a TTM value of $40.8 million through Dec 2023, down 21.94%, and an annual FY2025 reading of $7.7 million, down 87.74% over the prior year.
  • Capital Expenditures was $3.4 million for Q4 2023 at Ginkgo Bioworks Holdings, down from $4.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $25.6 million in Q4 2022 and bottomed at $3.4 million in Q4 2023.
  • Average Capital Expenditures over 4 years is $13.0 million, with a median of $13.5 million recorded in 2022.
  • Peak annual rise in Capital Expenditures hit 443.04% in 2023, while the deepest fall reached 86.56% in 2023.
  • Year by year, Capital Expenditures stood at $19.4 million in 2020, then tumbled by 73.66% to $5.1 million in 2021, then soared by 401.47% to $25.6 million in 2022, then crashed by 86.56% to $3.4 million in 2023.
  • Business Quant data shows Capital Expenditures for DNA at $3.4 million in Q4 2023, $4.4 million in Q3 2023, and $13.5 million in Q2 2023.